Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
US10975055B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 22, 2017 |
| Grant date | Apr 13, 2021 |
| Priority date | — |
| Expiry date | Nov 22, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D413/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention provides novel compounds of Formula (I′), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma)), inflammatory diseases, autoinflammatory diseases, and autoimmune diseases in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as an interleukin-1 receptor-associated kinase (IRAK) (e.g., IRAKI and/or IRAK4) in the subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.